Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.
Florida resident David Vega is suing Merck Sharp & Dohme Corp. for the injuries he sustained from ingesting the diabetic medication Januvia, alleging that he was diagnosed with pancreatic cancer as a direct result of taking Januvia.
Vega started taking Januvia in January 2006 to manage his type-2 diabetes. He stayed on the prescription until May 8, 2009, and was diagnosed with pancreatic cancer on April 12, 2009. According to the Januvia lawsuit, Vega was taken off the medication because he was exhibiting symptoms from the condition, which tests later confirmed.
The Januvia lawsuit argues that there were no warnings or indications on Januvia’s label regarding the possibility of contracting pancreatic cancer. Vega and his wife expressed their disappointment knowing that pancreatic cancer is known for being one of the most difficult cancers to treat, notwithstanding its aggressive nature.
Vega contends that Merck should have warned him and other patients about Januvia’s association with pancreatic cancer. He relied on the information given at the time of Januvia was prescribed and would have never taken the medication if he had earlier knowledge of the possibility of contracting pancreatic cancer.
He is suing Merck on charges of negligence, false advertising, concealing information and misrepresenting a product.
Diabetes Drugs Linked to Pancreatic Cancer
Januvia is one of the best-selling drugs in America, with sales topping $919 million in the first quarter of 2012. It was approved for the U.S. market on Oct. 17, 2006 to treat symptoms of type-2 diabetes. Coupled with healthy diet and proper exercise routine, the patient is expected to live a healthy and longer life. Studies, however, have linked Januvia, along with Janumet, Byetta, and Victoza to the development of pancreatic cancer.
Studies have shown an increase of pancreatic cancer in patients taking DDP-4 inhibitors like Januvia, compared to those who used other diabetic medications.
This Januvia lawsuit is part of the multidistrict litigation (MDL) movement, MDL 2452.
This Januvia lawsuit is David Vega v Merck Sharp & Dohme Corp. Case No. 3:13-cv-02877-AJB-MDD, in the U.S. District Court in Southern California.
In general, Januvia pancreatic cancer lawsuits are filed individually by each plaintiff and are not class actions.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or class action lawsuit is best for you. Hurry — statutes of limitations may apply.
ATTORNEY ADVERTISING
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2024 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
Get Help – It’s Free
Join a Free Januvia, Janumet, Byetta, Victoza Cancer Class Action Lawsuit Investigation
If you or your loved one took Januvia, Victoza, Janumet or Byetta and were diagnosed with pancreatic cancer or thyroid cancer, you have a legal claim. See if you qualify by filling out the short form below.
An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.
Oops! We could not locate your form.
